PHOENIX, AZ / ACCESSWIRE / April 10, 2019 / Uptick Newswire Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX) ("the Company"), an addiction treatment solutions company offering a unique approach to the treatment of alcohol and opioid use disorders. President and CEO, Brady Granier, joined Stock Day host Everett Jolly.
To begin the interview, Jolly asked Granier to give listeners an update on the Company's BICX102 naltrexone implant development process. Granier explained that the Company has achieved significant goals for this project, most notably the grant award of nearly $5.7 million from the National Institute on Drug Abuse (NDA) Currently, the Company is working toward FDA approval for BICX102 which the Company feels will make a significant impact on alcohol and opioid use disorders.
Jolly then asked about the Company's recent additions to their Board of Directors. Granier explained that the Company has added two experienced individuals, Louis
Jolly then inquired about the Company's recent announcement of their $6 million private placement and asked about the use of funds. Granier stated that some of the funds will be used to launch their future weight loss program, as well as for general operations and to aid in desired plans for a NASDAQ uplisting.
Jolly asked Granier how the Company plans to
To close the interview, Granier encouraged interested listeners to keep up-to-date on the Company's growth and new developments. He also added that individuals who need help with substance use disorder can visit www.beataddiction.com for more information.
To hear Brady Granier's entire interview, follow the link to the podcast here: https://upticknewswire.com/featured-interview-ceo-brady-granier-of-biocorrx-inc-otcqb-bicx-4/
Investors Hangout is a proud sponsor of "Stock Day," and Uptick Newswire encourages listeners to visit the company's message board at https://investorshangout.com/
About BioCorRx
BioCorRx Inc. (BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance abuse addiction and related disorders. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and
Twitter: @BioCorRxInc
LinkedIn: https://www.linkedin.com/company/biocorrx-inc/
Facebook: @BioCorRx
Instagram: @biocorrx_inc
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
[email protected]
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
[email protected]
Media Relations Contact:
Kyle Porter
CMW Media
[email protected]
(858) 264-6600
About Uptick Newswire and the "Stock Day" Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets.
602-441-3474
https://upticknewswire.com/
SOURCE: Uptick Newswire